p53 involvement in activation of the cytokeratin 8 gene in tumor cell lines

Anticancer Research

Volumn 16, Issue 1, 1996, Pages 105-112

  Mukhopadhyay, Tapas ^a   Roth, Jack A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cytokeratin; Lung cancer; p53

Indexed keywords

CYTOKERATIN; OLIGONUCLEOTIDE; PROTEIN P53;

ARTICLE; BINDING SITE; CANCER CELL CULTURE; CONTROLLED STUDY; DELETION MUTANT; DNA SEQUENCE; DNA TRANSFECTION; EXPRESSION VECTOR; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE INDUCTION; HELA CELL; HUMAN; HUMAN CELL; LUNG CANCER; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; TANDEM REPEAT; TRANSACTIVATION; TRANSCRIPTION INITIATION; TUMOR CELL;

BASE SEQUENCE; BINDING SITES; CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; KERATINS; LUNG NEOPLASMS; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS (GENETICS); TRANS-ACTIVATION (GENETICS); TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029997560     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Finlay CA, Hinds PW and Levinel AJ: The p53 proto-oncogene can act as a suppressor of transformation. Celll 57: 1083-1093, 1989.
2. Chen PL, Chen Y, Booksteinl R and Lee W-H: Genetic mechanisms of tumor suppression by the human p53 gene. Science 250: 1576-1580, 1990.
3. Baker S, Markowitz S, Fearon E, Wilson J and Vogelstein B: Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249: 912-915, 1990.
4. Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-Kimhi Oand Oren M: Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci USA 86: 8763-8767, 1989.
5. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr CA, Butal JS and Bradley A: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221, 1992.
6. Hall A, Marshall CJ, and Spurrnkweiss RA: Identification of transforming genes in two human sarcoma cell lines as a new member of the ras gene family located on chromosome 1. Nature 303: 396-400, 1983.
7. Lane DP p53: guardian of the genome. Nature 358: 15-16, 1992.
8. Fritsche M, Haessler C and Brandner G: Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 8: 307-318, 1993.
9. Yonish-Rouach E, Grunwald D, Wilder S, Kimchi A, May E, Lawrence J-J, May P, and Oren M: p53-mediated cell death, relationship to cell cycle control. Mol and Cell Biol 13 (3): 1415-1423, 1993.
10. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991.
11. Kuerbitz SJ, Plunkett BS, Walsh WV and Kastan MB: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89: 7491-7495, 1992.
12. Lowe SW, Ruley HE, Jacks T and Housman DE: p53-dependent apoptobis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993.
13. Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B and Fornace JrAJ: A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxiatelangiectasia. Cell 71: 587-597, 1992.
14. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML and Wythe AH Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362: 849-852, 1993.
15. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T and Tisty TD: Altered cell cycle arrest and gene amplification potential x accompany loss of wild-type p53 Cell 70: 923-935, 1992.
16. Yin YX, Tainsky MA, Bischoff FZ, Strong LC and Wahl GM: Wildtype p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70 937-948, 1992
17. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC and Vogelstein B: Mutations in the p53 gene occur in diverse human tumor types. Nature 342: 705-708, 1989.
18. Ahuja H, Bar-Eli M, Advani SH, Benchimol S and Cline MJ. Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. Proc Natl Acad Sci USA 86: 6783-6787, 1989.
19. Greenblatt MS, Bennett WP, Hollstein M and Harris CC: Mutations in the p53 tumor suppressor genes: clues to cancer etiology and molecular pathogenesis. Cancer Res 54. 4855-4878, 1994.
20. Sarnow P, Sullivan CA and Levine AJ: A monoclonal antibody detecting the adenovirus type 5 E1b-58Kd tumor antigen: characterization of the E1b-58Kd tumor antigen in adenovirus-infected and -transformed cells Virol 120: 510-517, 1982.
21. Scheffner M, Werness BA, Huibregtse JM, Levine AJ and Howley PM: The E6 oncoprotein encoded by human papilloma virus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136, 1990.
22. Werness, B.A., Levine, A J., and Howley, P.M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science, 248: 76-79, 1990.
23. Fields S and Jang SK Presence of a potent transcription activating sequence in the p53 protein. Science 249: 1046-1051, 1990.
24. Raycroft L, WuH and Lozano G: Transcriptional activation by wildtype but not transforming mutants of the p53 anti-oncogene Science, 249: 1049-1051, 1990.
25. Santhanam U, Ray A and Sehgal, PB: Repression of the interleukin-6 gene promoter by p53 and the retinoblastoma susceptibility gene products. Proc Natl Acad Sci USA 88. 7605-7609, 1991.
26. O'Rourke RW, Miller CW, Kato GJ, Simon KJ, Chen DL, Dang CV and Koeffler HP: A potential transcriptional activation element in the p53 protein. Oncogene 5: 1829-1832, 1990.
27. Funk WD, Pak DT, Karas RH, Wright WE and Shay JW: A transcriptionally active DNA-binding site for human p53 protein complexes. Mol and Cell Biol 12. 2866-2871, 1992.
28. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer E, Kinzler KW and Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75 817-825, 1993.
29. Kern SE, Pietenpol JA, Seymour A, Kinzler KW and Vogelstein B: Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256: 827-830, 1992.
30. Weintraub, H., Hauschka, S., and Tapscott, S.J. The MCK enhancer contains a p53 responsive element. Proc Natl Acad Sci USA, 88: 4570-4571, 1991.
31. Zambetti GP, Olson D, Labow M and Levine AJ: A mutant p53 protein is required for maintenance of the transformed phenotype in cells transformed with p53 plus ras cDNAs Proc Natl Acad Sci USA 89: 3952-3956, 1992.
32. Barak Y, Juven T, Haffner R and Oren M: Mdm2 expression is induced by wild-type p53 activity. EMBO J 12: 461-468, 1993.
33. Zauberman, A., Barak, Y., Ragimov, N., Levy, N., and Oren, M. Sequence-specific DNA binding by p53. Identification of target sites and lack of binding to p53-MDM2 complex. EMBO J 12: 2799-2808, 1993.
34. Cai DW, Mukhopadhyay T and Roth JA: Suppresion of lung cancer cell growth by ribozyme-mediated modification of p53 pre-mRNA. Cancer Therapy 2: 199-205, 1995.
35. Rosenthal N: Identification of regulatory elements of cloned genes with functional assays. Methods in Enzymology 752: 704-720, 1987.
36. Gorman CM, Moffat LF and Howard BH: Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol and Cell Biol 2(9): 1044-1051, 1982.
37. Zhang W, Funk WD, Wright WE, Shay JW and Deisseroth AB: Novel DNA binding of p53 mutants and their role in transcriptional activation. Oncogene 8: 2555-2559, 1993.
38. Kozmik Z and Paces V: Multiple bandshift assay: rapid identification and cloning of DNA fragments containing specific protein-binding sites. Gene 90: 287-291, 1990.
39. Chomczymsky P and Sacchi, N. Methods of RNA isolation by acid guanidinum thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
40. Krauss, S. and Frank, W.W. Organization and sequence of the human gene encoding cytokeratin 8. Gene 86 241-249, 1990.
41. Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases Cell 75: 805-816, 1993.
42. El-Deiry WS, Harper JW and O'Connor PM: WAF1/CIP1 is induced in p53-mediated G1 arrestandapoptosis. Cancer Res 54: 1159-1174, 1994.
43. Moll R, Franke WW and Schiller DL: The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 31: 11-24, 1982.
44. Steinert PM and Roop, DR. Molecular and cellular biology of intermediate filaments. Ann Rev Biochem 57: 593-625, 1988.
45. Trask DK, Band V, Zajchowski DA, Yaswen P, Suh T and Sager R: Keratins as markers that distinguish normal and tumor-derived mammary epithelial cells. Proc Natl Acad Sci USA, 87: 2319-2323, 1990.
46. Chu THT, Martinez I, Sheay WC and Dornburg R: Cell targeting with retroviral vector particles containing antibody-envelope fusion proteins. Gene Therapy 1. 292-299, 1994
47. Zajchowski D, Band V, Track DK, Kling D. Connolly JL and Sager R: Suppression of tumor-forming ability and related traits in MCF-7 human breast cancer cells by fusion with immortal mammary epithelial cells. Proc Natl Acad Sci USA 87: 2314-2318, 1990.